Nippon Shinyaku Co., Ltd. (TYO:4516)
4,201.00
+111.00 (2.71%)
May 29, 2026, 3:30 PM JST
Nippon Shinyaku Revenue
In the fiscal year ending March 31, 2026, Nippon Shinyaku had annual revenue of 170.77B JPY with 6.58% growth. Nippon Shinyaku had revenue of 43.64B in the quarter ending March 31, 2026, with 12.14% growth.
Revenue
170.77B
Revenue Growth
+6.58%
P/S Ratio
1.66
Revenue / Employee
76.14M
Employees
2,243
Market Cap
283.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 170.77B | 10.54B | 6.58% |
| Mar 31, 2025 | 160.23B | 11.98B | 8.08% |
| Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
| Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
| Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Toho Holdings | 1.55T |
| Sumitomo Pharma | 453.29B |
| Towa Pharmaceutical | 273.71B |
| Sawai Group Holdings | 201.68B |
| Tsumura & Co. | 192.62B |
| KYORIN Pharmaceutical | 126.26B |
| Mochida Pharmaceutical | 116.95B |
| Kissei Pharmaceutical | 97.41B |